Notice on Convening the 2nd Extraordinary General Meeting in 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Notice on Convening the 2nd Extraordinary General Meeting in 2026
Filed with SSE · · 6 pages · Chinese
Release
Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT3306 Combined with BAT8008 for Treatment for Advanced Solid Tumors
- Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Progress in Commercialization Agreement with STADA for BAT2506 (Golimumab) Injection
- Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in India
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT8008 Combined with BAT1006 and Trastuzumab of Advanced Solid Tumors
- Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Usymro (Ustekinumab Injection) by UK MHRA
Later from Bio-Thera Solutions
- Announcement on Loan Application Business of the Wholly-owned Subsidiary and the Company's Provision of Guarantee
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT8013 for Injection
- Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
- Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi(R) and Simponi Aria(R)
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions